Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 7, 2020

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2030

Conditions

Mantle Cell Lymphoma Recurrent

Interventions

COMBINATION_PRODUCT

ibrutinib and Tisagenlecleucel

Single-arm study investigating combination of ibrutinib and Tisagenlecleucel treatment

Trial Locations (1)

Peter Mac Callum Cancer Centre, Melbourne